NCT06693908View on ClinicalTrials.gov

A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

April 3, 2026

Study Completion Date

May 6, 2026

Conditions
Moderate to Severe Ulcerative Colitis
Interventions
DRUG

Vixarelimab

Vixarelimab will be administered as per the schedule specified.

Trial Locations (1)

10117

RECRUITING

Charité Research Organisation GmbH, Berlin

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY